EUVIMEDEUVIMED entdecken
Crossref

Auckland Sarcoma Unit Experience of Epithelioid Haemangioendothelioma

Joshua Mitchell iD, Claire Paul, Andrew Johnston

ANZ Journal of Surgery · 2025

DOI: 10.1111/ans.70337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ANZ Journal of Surgery, 2025. Verfasst von Joshua Mitchell und 2 weiteren Autor:innen. Beteiligte Einrichtung: Auckland City Hospital, Auckland, New Zealand. Hauptthemen laut MEDLINE: Hemangioendothelioma, Epithelioid. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epithelioid haemangioendothelioma ( EHE ) is a rare vascular sarcoma of endothelial origin, characterized by heterogeneous clinical presentations with limited consensus on optimal management. This study aims to describe the incidence, clinical features, treatment, and outcomes of EHE within the Auckland regional sarcoma unit.

Methods

A retrospective review was conducted of 20 patients diagnosed with histological confirmed EHE between 1999 and 2025, managed by the Auckland Sarcoma Unit, which receives referrals across the North Island of New Zealand. Data was extracted from electronic medical records, and incomplete records were excluded. Variables analyzed included incidence, demographics, tumor location, metastatic patterns, treatment modalities, and mortality.

Results

Twenty cases of EHE were identified in the North Island of New Zealand (1999–2025), yielding an estimated annual incidence of 0.19 per 1,000,000. The mean age at diagnosis was 57 years, with 65% female. The lower limb (50%) and liver (20%) were the most common primary sites; bony primaries accounted for 20% of cases. 50% of patients presented with metastatic disease. Metastases occurred predominantly in the lungs (60%), liver (30%), and bones (15%). Surgical resection was the main treatment for localized disease (82%), while metastatic cases were most often managed with active surveillance (56%). No patients received systemic chemotherapy. Recurrence occurred in three patients who presented with primary disease (27%). Overall mortality was 45%, higher in patients with metastasis at diagnosis (70% vs. 22%). Cumulative mortality at 1, 3, and 5 years was 15%, 25%, and 35%, respectively.

Conclusion

This is the largest reported case series of EHE in New Zealand, highlighting its rarity, variable clinical course, and poor prognosis. The findings underscore the need for improved data collection and international collaboration to inform management strategies for EHE .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemangioendothelioma, EpithelioidHumansFemaleNew ZealandMaleRetrospective StudiesMiddle AgedAgedAdultIncidenceLiver Neoplasms

Autor:innen und Institutionen

  • Auckland City Hospital, Auckland, New Zealand.

ORCID-Profile: Joshua Mitchell

Zitieren

APA

Mitchell, J., Paul, C., & Johnston, A. (2025). Auckland Sarcoma Unit Experience of Epithelioid Haemangioendothelioma. ANZ Journal of Surgery. https://doi.org/10.1111/ans.70337

Vancouver

Mitchell J, Paul C, Johnston A. Auckland Sarcoma Unit Experience of Epithelioid Haemangioendothelioma. ANZ Journal of Surgery. 2025. doi:10.1111/ans.70337

BibTeX
@article{Mitchell2025,
  author = {Mitchell, Joshua and Paul, Claire and Johnston, Andrew},
  title = {Auckland Sarcoma Unit Experience of Epithelioid Haemangioendothelioma},
  journal = {ANZ Journal of Surgery},
  year = {2025},
  doi = {10.1111/ans.70337}
}
Kostenlos starten →